Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection

Archives of Surgery

Volumn 146, Issue 6, 2011, Pages 724-732

  Norton, Jeffrey A ^a   Harris, Edmund J ^a   Chen, Yijun ^a   Visser, Brendan C ^a   Poultsides, George A ^a   Kunz, Pamela C ^a   Fisher, George A ^a   Jensen, Robert T ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DATA BASE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEART METASTASIS; HUMAN; LIVER METASTASIS; LIVER RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; NATIONAL HEALTH ORGANIZATION; OVERALL SURVIVAL; PANCREAS ISLET CELL TUMOR; PANCREAS RESECTION; PRIORITY JOURNAL; RECURRENT DISEASE; SPLENIC VEIN; SUPERIOR MESENTERIC ARTERY; SUPERIOR MESENTERIC VEIN; SURGICAL ANATOMY; SURGICAL MORTALITY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; TUMOR VOLUME; VASCULAR METASTASIS; WEDGE RESECTION;

ADULT; AGED; FEMALE; GASTRINOMA; GLUCAGONOMA; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 79959351349     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.2011.129     Document Type: Article

References (99)

1. Phan GQ, Yeo CJ, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg. 1998;2(5):472-482.
2. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20(11):2633-2642. (Pubitemid 34575635)
3. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240(5):757-773.
4. Jensen RT. Natural history of digestive endocrine tumors. In: Mignon M, Colombel JF, eds. Recent Advances in Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumors. Paris, France: John Libbey Eurotext Publishing Co; 1999:192-219.
5. Madeira I, Terris B, Voss M, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998;43(3):422-427. (Pubitemid 28414926)
6. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12(4):1083-1092. (Pubitemid 41815799)
7. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14(23):7798-7803.
8. Bok EJ, Cho KJ, Williams DM, Brady TM, Weiss CA, Forrest ME. Venous involvement in islet cell tumors of the pancreas. AJR Am J Roentgenol. 1984;142(2):319-322. (Pubitemid 14184667)
9. Hellman P, Andersson M, Rastad J, et al. Surgical strategy for large or malignant endocrine pancreatic tumors. World J Surg. 2000;24(11):1353-1360.
10. Stafford Johnson DB, Francis IR, Eckhauser FE, Knol JA, Chang AE. Dual-phase helical CT of nonfunctioning islet cell tumors. J Comput Assist Tomogr. 1998;22(1):59-63. (Pubitemid 28087320)
11. Wray CJ, Ahmad SA, Matthews JB, Lowy AM. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology. 2005;128(6):1626-1641. (Pubitemid 40692556)
12. La Rosa S, Rigoli E, Uccella S, Novario R, Capella C. Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours. Histopathology. 2007;50(5):597-606. (Pubitemid 46495832)
13. Deshpande V, Fernandez-del Castillo C, Muzikansky A, et al. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol. 2004;28(9):1145-1153. (Pubitemid 39121608)
14. Buchs NC, Chilcott M, Poletti PA, Buhler LH, Morel P. Vascular invasion in pancreatic cancer: imaging modalities, preoperative diagnosis and surgical management. World J Gastroenterol. 2010;16(7):818-831.
15. Ballian N, Loeffler AG, Rajamanickam V, Norstedt PA, Weber SM, Cho CS. A simplified prognostic system for resected pancreatic neuroendocrine neoplasms. HPB (Oxford). 2009;11(5):422-428.
16. Evans DB, Skibber JM, Lee JE, et al. Nonfunctioning islet cell carcinoma of the pancreas. Surgery. 1993;114(6):1175-1182..
17. Martin RC II, Scoggins CR, Egnatashvili V, Staley CA, McMasters KM, Kooby DA. Arterial and venous resection for pancreatic adenocarcinoma: operative and long-term outcomes. Arch Surg. 2009;144(2):154-159.
18. Glanemann M, Shi B, Liang F, et al. Surgical strategies for treatment of malignant pancreatic tumors: extended, standard or local surgery? World J Surg Oncol. 2008;6:123. doi:10.1186/1477-7819-6-123.
19. Siriwardana HP, Siriwardena AK. Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg. 2006;93(6):662-673. (Pubitemid 43886017)
20. Zhao WY, Luo M, Sun YW, et al. Computed tomography in diagnosing vascular invasion in pancreatic and periampullary cancers: a systematic review and meta-analysis. Hepatobiliary Pancreat Dis Int. 2009;8(5):457-464.
21. Noone TC, Hosey J, Firat Z, Semelka RC. Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab. 2005;19(2):195-211. (Pubitemid 40347811)
22. Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma: a contraindication for resection? Ann Surg. 1996;224(3):342-349.
23. Tseng JF, Tamm EP, Lee JE, Pisters PW, Evans DB. Venous resection in pancreatic cancer surgery. Best Pract Res Clin Gastroenterol. 2006;20(2):349-364.
24. Ramacciato G, Mercantini P, Petrucciani N, et al. Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma? Ann Surg Oncol. 2009;16(4):817-825.
25. Song TK, Harris EJ Jr, Raghavan S, Norton JA. Major blood vessel reconstruction during sarcoma surgery. Arch Surg. 2009;144(9):817-822.
26. Obuz F, Bora S, Sarioǧlu S. Malignant islet cell tumor of the pancreas associated with portal venous thrombus. Eur Radiol. 2001;11(9):1642-1644. (Pubitemid 32821372)
27. Handa M, Nakada T, Kajitsuka S, Hirose M, Sato Y. Portosystemic A-V fistula and portal hypertension associated with islet-cell tumor of the pancreas [in Japanese]. Nippon Geka Gakkai Zasshi. 1985;86(8):953-958.
28. Rusher AH, Henson K. Metastatic malignant insulinoma: debulking for palliation of symptoms. J Ark Med Soc. 1991;88(6):267-269.
29. Sakamoto E, Hasegawa H, Ogiso S, et al. Curative resection for a pancreatic endocrine carcinoma involving the portal vein. Hepatogastroenterology. 2004;51(60):1849-1851. (Pubitemid 39389795)
30. Kawakami H, Kuwatani M, Hirano S, et al. Pancreatic endocrine tumors with intraductal growth into the main pancreatic duct and tumor thrombus within the portal vein: a case report and review of the literature. Intern Med. 2007;46(6):273-277. (Pubitemid 46488394)
31. Akatsu T, Aiura K, Shimazu M, et al. Successful pancreatectomy with en-bloc resection of the celiac artery and portal vein for pancreatic endocrine carcinoma. Hepatogastroenterology. 2007;54(76):1269-1271. (Pubitemid 47013951)
32. Yamato H, Kawakami H, Kuwatani M, et al. Pancreatic carcinoma associated with portal vein tumor thrombus: three case reports. Intern Med. 2009;48(3):143-150.
33. Bedirli A, Patiroglu TE, Sakrak O, Aritas Y. Portal vein resection for a portal vein thrombus caused by nonfunctioning islet cell carcinoma: report of a case. Surg Today. 2004;34(9):802-804. (Pubitemid 39208374)
34. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Ann Surg. 2003;237(5):650-659. (Pubitemid 38174531)
35. Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999;341(9):635-644.
36. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg. 2004;239(5):617-625.
37. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg. 2001;234(4):495-506.
38. Norton JA, Doherty GM, Fraker DL, et al. Surgical treatment of localized gastrinoma within the liver: a prospective study. Surgery. 1998;124(6):1145- 1152.
39. Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg. 2003;138(8):859-866.
40. Fraker DL, Norton JA, Alexander HR, Venzon DJ, Jensen RT. Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg. 1994;220(3):320-330. (Pubitemid 24313225)
41. Norton JA. Surgical treatment and prognosis of gastrinoma. Best Pract Res Clin Gastroenterol. 2005;19(5):799-805.
42. Termanini B, Gibril F, Reynolds JC, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology. 1997;112(2):335-347. (Pubitemid 27078820)
43. Alexander HR, Fraker DL, Norton JA, et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg. 1998;228(2):228-238. (Pubitemid 30191719)
44. Gibril F, Reynolds JC, Chen CC, et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med. 1999;40(4):539-553. (Pubitemid 29171794)
45. Krudy AG, Doppman JL, Jensen RT, et al. Localization of islet cell tumors by dynamic CT: comparison with plain CT, arteriography, sonography, and venous sampling. AJR Am J Roentgenol. 1984;143(3):585-589. (Pubitemid 14067875)
46. Termanini B, Gibril F, Doppman JL, et al. Distinguishing small hepatic hemangiomas from vascular liver metastases in gastrinoma: use of a somatostatinreceptor scintigraphic agent. Radiology. 1997;202(1):151-158. (Pubitemid 27024121)
47. Sugg SL, Norton JA, Fraker DL, et al. A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg. 1993;218(2):138-144.
48. MacFarlane MP, Fraker DL, Alexander HR, Norton JA, Lubensky I, Jensen RT. Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. Surgery. 1995;118(6):973-980.
49. Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg. 2006;244(3):410-419.
50. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134(6):1057-1065.
51. Noda S, Norton JA, Jensen RT, Gay WA Jr. Surgical resection of intracardiac gastrinoma. Ann Thorac Surg. 1999;67(2):532-533.
52. Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine (Baltimore). 2000;79(6):379-411.
53. Roy PK, Venzon DJ, Feigenbaum KM, et al. Gastric secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis- a prospective NIH study of 235 patients and review of the literature in 984 cases. Medicine (Baltimore). 2001;80(3):189-222. (Pubitemid 32466460)
54. Raufman JP, Collins SM, Pandol SJ, et al. Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. Gastroenterology. 1983;84(1):108-113. (Pubitemid 13198296)
55. Jensen RT, Niederle B, Mitry E, et al; Frascati Consensus Conference; European Neuroendocrine Tumor Society. Gastrinoma (duodenal and pancreatic). Neuroendocrinology. 2006;84(3):173-182.
56. Termanini B, Gibril F, Sutliff VE III, Yu F, Venzon DJ, Jensen RT. Effect of longterm gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med. 1998;104(5):422-430. (Pubitemid 28274845)
57. Norton JA, Kahn CR, Schiebinger R, Gorschboth C, Brennan MF. Amino acid deficiency and the skin rash associated with glucagonoma. Ann Intern Med. 1979;91(2):213-215.
58. Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore). 2004;83(1):43-83. (Pubitemid 38124855)
59. Fishbeyn VA, Norton JA, Benya RV, et al. Assessment and prediction of longterm cure in patients with the Zollinger-Ellison syndrome: the best approach. Ann Intern Med. 1993;119(3):199-206.
60. Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology. 1995;108(6):1637-1649.
61. Benya RV, Metz DC, Venzon DJ, et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I. Am J Med. 1994;97(5):436-444. (Pubitemid 24345595)
62. Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome: results of a 10-year prospective study. Ann Surg. 1992;215(1):8-18.
63. Norton JA. Intraoperative methods to stage and localize pancreatic and duodenal tumors. Ann Oncol. 1999;10(suppl 4):182-184.
64. Norton JA. Endocrine tumours of the gastrointestinal tract: surgical treatment of neuroendocrine metastases. Best Pract Res Clin Gastroenterol. 2005;19(4):577-583.
65. Arnold WS, Fraker DL, Alexander HR, Weber HC, Norton JA, Jensen RT. Apparent lymph node primary gastrinoma. Surgery. 1994;116(6):1123-1129.
66. Jaskowiak NT, Fraker DL, Alexander HR, Norton JA, Doppman JL, Jensen RT. Is reoperation for gastrinoma excision indicated in Zollinger-Ellison syndrome? Surgery. 1996;120(6):1055-1062.
67. von Schrenck T, Howard JM, Doppman JL, et al. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology. 1988;94(6):1326-1334.
68. Shojamanesh H, Gibril F, Louie A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer. 2002;94(2):331-343. (Pubitemid 34081361)
69. Pisegna JR, Slimak GG, Doppman JL, et al. An evaluation of human recombinant alpha interferon in patients with metastatic gastrinoma. Gastroenterology. 1993;105(4):1179-1183. (Pubitemid 23281509)
70. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.JAm Stat Assoc. 1958;53:457-481.
71. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135(5):1469-1492.
72. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol. 1999;17(2):615-630. (Pubitemid 29075250)
73. Strosberg JR, Kvols LK. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs. 2007;16(2):219-224. (Pubitemid 46206635)
74. Eriksson J, Stålberg P, Nilsson A, et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg. 2008;32(5):930-938.
75. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am. 2003;12(1):231-242. (Pubitemid 36210867)
76. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29-37. (Pubitemid 36759176)
77. Steinmüller T, Kianmanesh R, Falconi M, et al; Frascati Consensus Conference participants. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008;87(1):47-62.
78. Gurusamy KS, Ramamoorthy R, Sharma D, Davidson BR. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev. 2009;(2):CD007060.
79. Pachera S, Yokoyama Y, Nishio H, et al. A rare surgical case of multiple liver resections for recurrent liver metastases from pancreatic gastrinoma: liver and vena cava resection. J Hepatobiliary Pancreat Surg. 2009;16(5):692-698.
80. Geehan DM, Kapcala LP, Saberinia M, Scovill WA. Intravascular tumor: a previously unreported finding of glucagonoma. South Med J. 1997;90(7):743-747. (Pubitemid 27304717)
81. Gold RP, Black TJ, Rotterdam H, Casarella WJ. Radiologic and pathologic characteristics of the WDHA syndrome. AJR Am J Roentgenol. 1976;127(3):397-401.
82. Fortner JG, Kim DK, Cubilla A, Turnbull A, Pahnke LD, Shils ME. Regional pancreatectomy: en bloc pancreatic, portal vein and lymph node resection. Ann Surg. 1977;186(1):42-50. (Pubitemid 8141582)
83. Metz DC, Benjamin SB. Islet cell carcinoma of the pancreas presenting as bleeding from isolated gastric varices: report of a case and review of the literature. Dig Dis Sci. 1991;36(2):241-244.
84. Ait-Ali A, Sall I, El-Kaoui H, et al. Medial pancreatectomy for a neuroendocrine tumor invading the splenic artery and vein. JOP. 2010;11(1):75-77.
85. Okuno M, Sakaguchi S, Nagayama M, et al. Nonfunctioning islet cell carcinoma presenting bleeding gastric varices and splenomegaly. Jpn J Surg. 1984;14(3):244-247. (Pubitemid 14009137)
86. Yamaguchi T, Takahashi H, Kagawa R, et al. Nonfunctioning pancreatic endocrine tumor presenting with hemorrhage from isolated gastric varices. Am Surg. 2005;71(12):1027-1030.
87. Chellappa M, Yee CK, Gill DS. Left-sided portal hypertension from malignant islet cell tumour of the pancrease: review with a case report. J R Coll Surg Edinb. 1986;31(4):251-252. (Pubitemid 17187188)
88. Bettini R, Boninsegna L, Mantovani W, et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol. 2008;19(5):903-908. (Pubitemid 351627305)
89. Thompson GB, van Heerden JA, Grant CS, Carney JA, Ilstrup DM. Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery. 1988;104(6):1011-1017. (Pubitemid 19011980)
90. Fendrich V, Waldmann J, Bartsch DK, Langer P. Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol. 2009;6(7):419-428.
91. Moertel CG. Karnofsky memorial lecture: an odyssey in the land of small tumors. J Clin Oncol. 1987;5(10):1502-1522.
92. Fendrich V, Langer P, Celik I, et al. An aggressive surgical approach leads to longterm survival in patients with pancreatic endocrine tumors. Ann Surg. 2006;244(6):845-853.
93. Kazanjian KK, Reber HA, Hines OJ. Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg. 2006;141(8):765-770.
94. Wolf JH, Long RJ, Miller FJ Jr, Jeffries GH. Pancreatic islet cell tumor presenting as bleeding gastric varices secondary to splenic vein occlusion. Am J Dig Dis. 1977;22(7):652-655. (Pubitemid 8151751)
95. Maclean N, Falconer CW, Gilmour IE, Webb FN. Islet cell tumours of the pancreas with portal varices and gastrointestinal haemorrhage. J R Coll Surg Edinb. 1970;15(4):206-212.
96. Watase M, Sakon M, Monden M, et al. A case of splenic vein occlusion caused by the intravenous tumor thrombus of nonfunctioning islet cell carcinoma. Surg Today. 1992;22(1):62-65.
97. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61-72.
98. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38-47.
99. Thomas AA, Rini BI, Stephenson AJ, et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol. 2009;182(3):881-886.